Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial

BACKGROUND: Given the scale of the ongoing COVID-19 pandemic, the development of vaccines based on different platforms is essential, particularly in light of emerging viral variants, the absence of information on vaccine-induced immune durability, and potential paediatric use. We aimed to assess the...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Lancet Infect Dis
Main Authors: Chappell, Keith J, Mordant, Francesca L, Li, Zheyi, Wijesundara, Danushka K, Ellenberg, Paula, Lackenby, Julia A, Cheung, Stacey T M, Modhiran, Naphak, Avumegah, Michael S, Henderson, Christina L, Hoger, Kym, Griffin, Paul, Bennet, Jillian, Hensen, Luca, Zhang, Wuji, Nguyen, Thi H O, Marrero-Hernandez, Sara, Selva, Kevin J, Chung, Amy W, Tran, Mai H, Tapley, Peter, Barnes, James, Reading, Patrick C, Nicholson, Suellen, Corby, Stavroula, Holgate, Thomas, Wines, Bruce D, Hogarth, P Mark, Kedzierska, Katherine, Purcell, Damian F J, Ranasinghe, Charani, Subbarao, Kanta, Watterson, Daniel, Young, Paul R, Munro, Trent P
פורמט: Artigo
שפה:Inglês
יצא לאור: Elsevier Ltd. 2021
נושאים:
Articles
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC8055208/
https://ncbi.nlm.nih.gov/pubmed/33887208
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(21)00200-0
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים